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Appropriate Timing of Fluoxetine and Statin
Delivery Reduces the Risk of Secondary
Bleeding in Ischemic Stroke Rats
Abstract
Background: Ongoing clinical trials are testing the effect of fluoxetine delivered
post-stroke where a majority of patients are taking statins. This study determined
the influence of the timing of administration of fluoxetine and statin on the final
infarct volume and the risk of secondary bleeding in an animal model of ischemic
stroke.
Methods and findings: Ischemic strokes were induced by endothelin-1 injection
into two cortical sites of 10-12 month old female rats, targeting the forelimb motor
cortex. Combined medications (5 mg/kg fluoxetine and 1 mg/kg simvastatin)
were orally administered either beginning 6-12 hours or 20-26 hours after stroke
induction and continued daily for 90 days. Infarct volumes were assessed at poststroke day 91 using Nissl stained coronal brain sections.
Control animals typically had 5-13 mm3 infarct volumes following endothelin-1
induced stroke. Animals that received fluoxetine and simvastatin (FS) beginning 2026 hours after stroke induction showed a strong trend of reduced infarct volume
(3±0.3447 mm3 SEM, P=0.0563). Earlier drug delivery (6-12 hours after stroke)
resulted in significantly larger infarct volumes (15.44.260 mm3 SEM, P=0.0157)
when the drug groups were directly compared. Examination of the infarcts
showed that earlier drug delivery induced secondary hemorrhagic infarcts, while
later delivery did not (P=0.0427; Fisher’s exact test).
Conclusion: There is a danger of secondary bleeding if fluoxetine and simvastatin
are combined within 6-12 hours of ischemic stroke induction in rats resulting in
larger infarct volumes. Delaying fluoxetine and simvastatin delivery to 20-26 hours
after stroke induction in rats, however, reduces infarct volume and significantly
lowers the risk of secondary hemorrhagic infarcts.
Keywords: Ischemic Stroke, Secondary Hemorrhagic Stroke, Fluoxetine,
Simvastatin, Infarct Volume
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Introduction
Only a small percentage of acute ischemic stroke patients
reach the hospital in time to be considered for treatment with
recombinant tissue plasminogen activator (rtPA),which can
minimize permanent brain damage and reduce the risk of longterm disability [1]. Fluoxetine, a selective serotonin reuptake
inhibitor (SSRI), has been recently shown to enhance motor
functional recovery after ischemic stroke [2,3]. Several ongoing

clinical trials are looking at the effect of Fluoxetine when
given 2-15 days following stroke onset, including the AFFINITY
(Assessment oF FluoxetINe In sTroke recoverY) trial in Australia,
the FOCUS (Fluoxetine Or Control Under Supervision) trial in
the United Kingdom, and the EFFECTS (Efficacy oF Fluoxetine–a
randomizEd Controlled Trial in Stroke) trial in Sweden [4]. Since
the majority of patients coming into the hospital are already
on statins due to dyslipidemia, the purpose of this study was to
examine whether administering fluoxetine at an earlier time-
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point after stroke onset in combination with a statin could
improve outcomes. In this study, we measured infarct volume
differences when fluoxetine was administered either 6-12 hours
or 20-26 hours after stroke induction in 10-12 month old rats.

Materials and Methods
Subjects
All animal work was approved by the Institutional Animal Care
and Use Committee at Wright State University, and all procedures
followed were in accordance with institutional guidelines.
Animals used were 10-12 month old female Sprague-Dawley rats
(generally 300-400 grams), obtained from Harlan Laboratories
(Indianapolis, IN) and fed Harlan rat chow. The specific groups
are indicated in Table 1.

Functional tests
Montoya staircase: Rats were fasted overnight and then placed
on a restricted diet consisting of 85% of their ad lib rat chow while
they were trained to pick up sucrose pellets on the Montoya
Staircase [5]. The Montoya Staircase consists of a raised platform
with seven stairwells on each side containing sucrose pellets
(three per stairwell) on each side of the platform, allowing left
and right forelimb function to be assessed. Training occurred
during the dark-phase and consisted of 15 minute trials inside
the Montoya Staircase with sucrose pellets that have been
painted with maple extract; the maple odor helps the rats locate
the sucrose pellets on the stair wells. Training generally lasts
anywhere from 10-14 days. At the end of the training period, the
rat’s pre-stroke performance was determined by the best overall
performance (total pellets taken) during the last three days of
training. Animals must have learned to pick up at least 9 pellets
with both their left and right forepaws or they were excluded
from the Montoya Staircase analysis. The majority of animals
learned to retrieve between 15-18 pellets with both paws. At 3-5
days post-stroke the rats were tested on the Montoya Staircase
again, and their best performance (total pellets taken) was used
as a measure of their post-stroke baseline performance. To
normalize their performance, we divided the number of pellets
taken by each paw post-stroke by the number of pellets taken by
each paw pre-stroke. Thus, when the quotient was 1, the animal
had fully regained pre-stroke function in a particular limb and
when the quotient was less than 1, the animal had a functional
deficit in that limb. Animals that failed to reach training criteria
on Montoya Staircases were tested on Forelimb Asymmetry.
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Forelimb asymmetry: Animals were placed in a clear vertical
cylinder and videotaped for 5 minutes. Rats would rear up and
touch the walls of the cylinder with their right and left forepaws
to explore their environment. Normally, pre-stroke, the majority
of rats showed little preference for the right or left paw during
this exploration behavior. However, when rats were again tested
on post-stroke day 4, they showed a preference for touching the
wall with their ipsilateral (right) paw, while they held their left
paw back toward their body. In this analysis we looked at the
percentage of touches to the wall by right or left paw post-stroke
and divided that by their pre-stroke performance percentages.
Again, when the quotient was 1, the animal had fully regained
pre-stroke function and when the quotient was less than 1,
the animal had a functional deficit in that limb. In this test in
particular, the increased percentage of right paw use gave us
values greater than 1.

Surgery for stroke induction
Anesthesia was induced with 5% isoflurane, and then the animals
were maintained on 2-2.5% isoflurane using an anesthesia mask
on the stereotactic apparatus (Stoelting Co., USA). The basic
surgical procedures are as described in a previous study[6],
with the following modifications: two holes were drilled in
the skull, with positions relative to Bregma of (0.0 mm A.P.,
2.5 mm M.L.) and (1.5 mm A.P., and 2.5 mm M.L.). The needle
containing endothelin-1 was inserted into both holes in the skull,
then lowered to a depth of 2 mm. One and one-half microliters
of endothelin-1 (600 pmol) was injected into each hole over a
period of about 5 minutes. These positions were chosen to target
the forelimb motor cortex in rats [7].

Treatment conditions
Two different time-points were chosen for initiating 5 mg/
kg fluoxetine and 1 mg/kg simvastatin after stroke induction:
6-12 hours (12 animals per group) and 20-26 hours (8 animals
per group). Animals were randomly assigned to either drug or
control group after the surgery, but before the baseline stroke
deficit was determined using either Montoya Staircase or
Forelimb Asymmetry tests. After drug treatment was begun, it
was continued daily for a period of 90 days, using voluntary oral
administration of the drugs [8]. Briefly, this involves putting the
drugs in a 4 gram ball of sugar cookie dough and allowing the
animals to eat it. Control animals receive the 4 gram ball of sugar
cookie dough with no drugs added.

Table 1 Characteristics of treatment groups. FS refers to fluoxetine and statin groups.
Group
6-12 hrs. Control
6-12 hrs. FS
20-26 hrs. Control
20-26 hrs. FS

2

Gender/ Strain
Female /
Sprague Dawley
Female/
Sprague Dawley
Female/
Sprague Dawley
Female/
Sprague Dawley

Weight at Stroke
(mean±SD)

Drugs (oral)

Age at Stroke

329 ± 21.4 gm

None

10.5 months

332 ± 30.9 gm

1 mg/kg statin
5 mg/kg fluoxetine

10.5 months

316 ± 19.5 gm

None

10.5 months

322 ± 27.6 gm

1 mg/kg statin
5 mg/kg fluoxetine

10.5 months
This article is available in: www.jneuro.com
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Histology
The animal was anesthetized with 100mg/kg, i.p. pentobarbital
(Euthasol®), then euthanized by cardiac perfusion with phosphatebuffered saline followed by 4% paraformaldehyde in phosphate
buffered saline. The brain was dissected out, the left hemisphere
marked, and the brain post-fixed 24 hours in 4% paraformaldehyde
in phosphate buffered saline. The brain was then put into a 30%
sucrose solution for three days, in preparation for cryosectioning.
Fifty micron coronal slices were cut on a cryostat and collected
into phosphate buffered saline. For infarct measurement, these
sections were mounted onto gel-subbed slides, then stained with
Nissl stain [6], dehydrated and coverslipped with DPX mountant
(Sigma-Aldrich).

Infarct measurement
Brightfield images were taken of the sections using a 4X
objective, then montaged using Adobe Photoshop 7.0 (Adobe
Systems Inc, San Jose CA, USA) into a complete picture of any
damaged regions of the brain. Area of the infarct was determined
with ImageJ software from NIH. We determined infarct area
(mm2) for every third or fourth slice, then multiplied by the slice
thickness (mm) and either 3 or 4 respectively, to determine the
complete infarct volume in mm3. Individuals determining the
infarct volume were blinded to the animal group (control group
or fluoxetine-simvastatin group). We lost four brains in the
fluoxetine-simvastatin treated group for 6-12 hour administration
and two of the fluoxetine-simvastatin treated group (20-26 hour
administration) due to damage while cutting the brains on the
microtome (shattering), which made the brain slices impossible
to mount on slides or damage to brain while dissecting that made
determination of complete infarct volume impossible.

Statistics
An unpaired t-test with Welch’s correction for unequal variances
was used for statistical comparison of the infarct volumes (Prism
6.0, GraphPad Software Inc. San Diego, USA). Figure 1 shows
means and standard error of the means, with individual infarct
volumes given by closed symbols clustered around means.
Sample sizes are given in the figure legends. The online relative
risk calculator from the MedCalc site (www.medcalc.org/calc/
relative_risk.php) was used to determine the relative risk of the
stroke rats developing secondary hemorrhagic stroke due to drug
combination administration time and Fisher’s exact test (twotailed) was used to determine if there was a statistical difference
in the occurrence of secondary hemorrhagic infarcts between the
two delivery times.

Results
Functional assessment
Female Sprague-Dawley rats (10-12 months old, 300-400 grams)
were initially trained to pick up sucrose pellets in the Montoya
Staircase [5] and also tested for forelimb bias using the Forelimb
Asymmetry Test [6]. We chose old rats as an animal model to
better model the human stroke population, as neurogenesis is
decreased in both humans and animals with age [9,10], and the
© Under License of Creative Commons Attribution 3.0 License
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drugs chosen would work to increase neurogenesis [11-14]. Three
days prior to the stroke, the rats were introduced to the vehicle
that would contain their drugs or serve as a vehicle control (4
grams of sugar cookie dough, Pillsbury®) to allow them to get
over their avoidance of novel foods; their pre-stroke baseline
performance in Montoya Staircase and Forelimb Asymmetry was
assessed. To be included in the functional analysis, rats had to pick
up at least 9 sucrose pellets with each forepaw in the Montoya
Staircase test and show at least a 20% functional deficit. The rats
displayed similar post-stroke function in the contralateral paw
in each of the time groups: in the 6-12 hours treatment groups,
the mean contralateral function was 0.30±0.32 (mean±SD) in
the FS group and 0.33±0.28 in the control group. In the 20-26
hours treatment groups, the post-stroke mean contralateral
function was 0.525±0.31 for the FS group and 0.37±0.27 for the
control group. There was no statistical difference in the functional
deficits on the contralateral forepaw between the drug and
control groups. In some cases, we would see a bilateral deficit,
and when those infarcts were examined, the infarcts generally
involved a portion of the corpus callosum. Infarcts were induced
with endothelin-1 injections at the forelimb motor cortex, and
drug treatment with 5 mg/kg fluoxetine and 1 mg/kg simvastatin
was begun either 6-12 hours OR 20-26 hours after stroke
induction. These drug dosages correlate to approximately a 40
mg fluoxetine dose and a 10 mg dose of simvastatin in humans
[15]. This amount of fluoxetine is about twice what is currently
being used in on-going clinical trials [3,4].

Exclusions
In this study, we examined infarct sizes in all animals that
underwent stroke and also displayed at least a 20% contralateral
deficit in the Montoya Staircase or Forelimb Asymmetry. In our
endothelin-1 induced stroke method, we positioned a needle
with endothelin-1 at a depth of 2 mm from the cortical surface
before injecting 600 pmoles of endothelin-1 into the site. This
movement of the needle through the cortex sometimes nicks a
blood vessel and causes some bleeding, which the endothelin-1
will generally stop for an interval. One of the animals in the control
group had substantial bleeding due to this needle damage of
blood vessels (Figure 3; Panel A: positive control for hemorrhagic
infarcts), which produced secondary hemorrhagic damage in this
animal and a huge infarct that spread far anterior and posterior
compared to our normal infarcts (total infarct volume of 53.20
mm3). Because this damage was due to a surgical artifact, and
not due to the endothelin-1 induced ischemic damage, it was not
included in this study. The only other reason that a rat brain was
excluded from this analysis was if the brain was damaged either
during dissection or during the cryostat sectioning, such that
we could not mount the individual slices or could not accurately
determine the entire infarct volume.

Infarct volumes vary with timing of fluoxetine,
statin administration
In Figure 1, infarct volumes were calculated on post-stroke day
91, with animals either receiving fluoxetine and simvastatin (FS
in figure, 5 mg/kg, and 1 mg/kg, respectively) or vehicle control,
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Figure 1 Infarct volume varies with timing of fluoxetine and simvastatin delivery after ischemic stroke.

Infarct volumes were assessed in rats at post-stroke day 91, and drug-treated rats received 5 mg/kg fluoxetine and 1 mg/
kg simvastatin daily in vehicle, beginning at the time indicated in the panel. FS in the figure refers to animals receiving
fluoxetine and simvastatin.
Panel A: Panel shows infarct volumes assessed in rats receiving either vehicle control (circles, N=8) and or drugs in vehicle
(squares, N=6) beginning 20-26 hours after ischemic stroke induction and continuing daily until the end of study. Infarct
volumes showed a strong trend of reduction, but just missed a significant difference (P=0.0563, Welch’s t-test) for the
fluoxetine and simvastatin group.
Panel B: Panel shows infarct volumes when either vehicle control (circles, N=8) or drugs in vehicle (squares, N=11) was
delivered 6-12 hours after ischemic stroke induction and continued daily until the end of study. Infarct volumes showed no
statistical difference (P=0.1347; Welch’s t-test).
Panel C: Panel shows direct comparison of infarct volumes for the group receiving fluoxetine and simvastatin with different
delivery times after stroke induction. The timing of delivery after stroke produced a significant difference in infarct volumes
(P=0.0157; Welch’s t-test), with the earlier timing producing a much larger infarct.

beginning either 6-12 hours or 20-26 hours after stroke induction
and continuing daily through post-stroke day 90. In Panel A,
we see a strong trend toward a reduction in infarct size in the
FS group (3.051±0.3447 mm3, mean±SEM; squares) compared
to control (6.277±0.14 mm3, mean±SEM; circles) when the
fluoxetine and simvastatin drug combination is administered
beginning 20-26 hours after the stroke (P=0.0569; Welch’s
correction on unpaired t-test with unequal variance), which was
an unexpected result. We did not think drug administration this
late after stroke induction would have any effect on the infarct
volume. The reduction in infarct volume has also correlated with
an increase in motor functional recovery, referenced in some of
our previous work [6]. We next tested whether an earlier time
point for drug delivery would result in further reduction of infarct
volume and greater functional recovery, administering the drugs
6-12 hours after stroke induction, a time period over which the
majority of stroke patients have been shown to arrive at the
hospital [1]. In Panel B, we see that drug delivery at an earlier time
point actually resulted in larger infarct volumes (15.24±4.26 mm3;
mean±SEM; squares) which were not statistically different from
control infarct volumes (9.775±2.786 mm3; mean±SEM; circles)
(P=0.1347; Welch’s correction for unpaired t-test with unequal
variance). In panel C, we directly compared the infarct volumes
in the two groups that received fluoxetine and simvastatin, just
looking at the effect the difference in delivery time (noted on the
X axis) had on the infarct volume. This data was simply taken from
panels A and B, re-plotted on the same scale and then compared
for statistical difference. Earlier delivery (6-12 hours after stroke)

4

resulted in statistically larger infarcts (circles; mean of 15.24
mm3) compared to later delivery times (20-26 hours after stroke;
squares; 3.051 mm3 mean) (P=0.017; Welch’s correction of
unpaired t-test with unequal variance). Since this was a surprising
result, we examined the infarcts closely to determine why the
infarct size was enlarged.

Histological evidence of secondary hemorrhagic
transformation in rats receiving fluoxetine and
statin at an early time point
In Figure 2, infarcts are shown (outlined with dashed lines) in
representative coronal brain sections for each of the relevant
groups. The endothelin-1 injection site was usually clearly seen
at the dorsal portion of the cortex as it is generally a hole in
the tissue at 91 days post-stroke, since it was the origin of the
infarct. In control animals (Panels A and C), we have generally
seen additional damage to the right side of this injection point,
representing perhaps reperfusion damage when the endothelin-1
was metabolized or eliminated, allowing blood flow to return
after approximately 24 hours [16]. Areas with very small surface
damage were not included in outlined infarcts just for clarity in
this figure, but they were included in the infarct analysis above. In
general, we did not see evidence of any secondary hemorrhagic
stroke in control animals, whether or not the control vehicle was
delivered at 6-12 hours after stroke (Panel A) or 20-26 hours after
stroke (Panel C).
Panel D shows the infarct size (largest in a series of brain sections)
from an animal given fluoxetine and simvastatin 20-26 hours after
This article is available in: www.jneuro.com
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Figure 2 Representative images showing coronal brain sections with infarcts from groups shown in
Figure 1.

Panel A: Control vehicle 6-12 hours after stroke induction. Coronal right hemisphere clearly
shows injection site for endothelin-1 and then enlarged infarct continuing from this initial
area of damage (outlined with dashed lines).
Panel B: Fluoxetine and simvastatin 6-12 hours after stroke induction. Coronal right
hemisphere shows posterior portion of injection infarct (near top of cortex, enclosed by
dashed lines) as well as a completely dissociated secondary hemorrhagic infarct (lower
portion of right hemisphere, enclosed with dashed lines). In a majority of images from this
group, we found evidence of secondary hemorrhagic infarcts appearing in either the right or
left hemisphere, which accounts for the larger infarct volumes associated with this group.
Panel C: Control vehicle 20-26 hours after stroke induction. Infarct size was similar to that
seen in Panel A; we just show the portion of the cortex with the infarct (outlined by dashed
lines).
Panel D: Fluoxetine and simvastatin 20-26 hours after stroke induction. This figure shows
the largest damage in a coronal section from this group, with the infarct centered around the
injection site (enclosed in dashed lines). The scale bar represents 500 microns.

stroke induction. You only see the original damage associated with
the endothelin-1 injection at the core of the infarct, but the rest
of the cortex appears to have normal Nissl staining. In contrast to
control animals, there does not appear to be damage to the right
of the original site, perhaps indicating that reperfusion damage
was minimized. Alternatively, the fluoxetine and simvastatin are
both known to increase growth factors in the brain, and we have
shown in a previous study [6] that one of these growth factors,
brain derived neurotrophic factor (BDNF), is elevated around
the site of the original infarct; this may allow tissue around the
original infarct to survive.
Out of 12 control animals with vehicle delivered at 6-12 hours,
we saw two that had possible signs of secondary hemorrhagic
infarcts (infarcts were located either far anterior or far posterior
and dissociated away from the original infarct). One of these
substantial bleeding occurred when lowering the needle into the
cortex, so was an artifact of the surgical procedure. An example
of this is shown in Figure 3, panel A, illustrating the extensive
© Under License of Creative Commons Attribution 3.0 License

bleed from surgical artifact compared to a possible secondary
hemorrhagic transformation. One control animal did show some
posterior lateral damage, which may have been caused by a
secondary hemorrhagic infarct, so we did include this animal when
we compared relative risk of secondary hemorrhagic infarcts. In
contrast, when we examined fluoxetine and simvastatin delivery
6-12 hours after stroke (Panel B), we found more evidence of
secondary hemorrhagic stroke, clearly dissociated from the
original endothelin-1 injection site (e.g. ventral location, location
in other hemisphere, far anterior or posterior to original injection
site): Six of the original 11 animals in the early delivery FS
group showed signs of secondary infarcts. The relative risk was
calculated to be 4.36 (95% CI=0.64-29.5) for these small groups
(6 positive outcomes and 5 negative outcomes) for the treated
group to have a bad outcome compared to control (1 positive and
7 negative).

Discussion
A number of animal studies have looked at fluoxetine
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Figure 3 Hemorrhagic infarcts in control rats.
Panel A: Positive control shows hemorrhagic infarct induced by excessive bleeding during the
stroke induction surgery (needle hit a blood vessel). Note that the secondary hemorrhagic
infarct (red arrow) is very posterior to our normal injection site infarct (black arrow) and is
completely dissociated from any cortical injury at the dorsal cortical surface.
Panels B and C show anterior and posterior sections, respectively, from our one control
rat that appeared to have a secondary hemorrhagic transformation. Possible secondary
hemorrhagic infarcts are marked with red arrows, while the endothelin-1 induced infarct is
marked by a black arrow.

administration in stroked animals or traumatic brain injury animals
and many have failed to see any positive effect of the fluoxetine
[17-19]. In several of these studies, neurogenesis is examined in
the dentate gyrus, with only cursory examination of neurogenesis
in lateral ventricles that are very posterior in the brain (to the side
of the hippocampus). Also, the delivery method for fluoxetine is
generally one which would induce stress in the animal (surgical
implantation of an osmotic pump delivering fluoxetine, daily
intraperitoneal injections of fluoxetine, oral gavage of fluoxetine,
etc.). We have seen increases in neurogenesis in older (10-12
month) rats in the subventricular zone (SVZ) of the anterior lateral
ventricles in the presence of fluoxetine when it is given with
voluntary oral administration, thus eliminating any stress with
administration of the fluoxetine. We also see functional recovery,
which correlates well with what is being seen in clinical trials of
the drug in stroke patients[2,20] or traumatic brain injury patients
[21]. Since stress has an inhibitory effect on neurogenesis and
fluoxetine generally has a positive effect [22,23], we believe that
care must be taken to eliminate stress when administering the
fluoxetine to animal models of disease, which our drug delivery
system accomplishes [8].
Both fluoxetine and simvastatin have been shown to increase
vascular endothelial growth factor (VEGF) [14,24]. In the early
delivery time, the formation of VEGF may cause bleeding because
the normal proteins involved in structural support of angiogenesis
are not yet available. In a study from Michael Chopp’s lab,
early delivery (within 1 hour of induction) of rhVEGF to middle
cerebral artery-occluded male Wistar rats showed signs of blood
brain barrier leakage and hemorrhagic transformation, while
later delivery (48 hours after stroke induction) did not [25]. This
study may be the basis for beginning the fluoxetine post-stroke
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treatment no earlier than the second day post-stroke in ongoing
Clinical Trials testing fluoxetine for motor recovery after stroke.
We do not have direct evidence for increased VEGF immediately
after drug administration yet, but from previous work on these
drugs, the preceding was a potential explanation for why we saw
hemorrhagic transformation at an earlier time point, but that
hemorrhagic transformation disappeared at a later time point,
although the drugs were exactly the same at both time points.
However, given the results of this study and another study from
this lab [6], it appears that giving fluoxetine 20-26 hours after
stroke induction not only promotes motor functional recovery,
but also reduces the infarct volume significantly compared to
giving the fluoxetine and simvastatin within 6-12 hours of stroke
induction.
We are currently performing studies where the rats are on the
statins prior to stroke induction, and fluoxetine is given at various
times after stroke, so that the drug delivery will correlate better
with what is seen during clinical trials with fluoxetine. We will
directly compare fluoxetine delivery at 6-12 hours, 20-26 hours
and 48-54 hours after stroke induction, and note impact on infarct
volume at 7 days post-stroke and any trend towards hemorrhagic
transformation.

Conclusion
The combination of simvastatin and fluoxetine increased the
relative risk (RR=4.36, 95% CI=0.64-29.5) of bleeding after
ischemic stroke if it is given 6-12 hours after stroke induction in
rats. However, delivery of simvastatin and fluoxetine 20-26 hours
after ischemic stroke in rats significantly reduces infarct size
compared to earlier delivery and shows a strong trend towards
infarct reduction compared to controls.
This article is available in: www.jneuro.com
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